Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2771-2786

  Misner, D L ^a   Frantz, C ^b   Guo, L ^c   Gralinski, M R ^d   Senese, P B ^d   Ly, J ^a,e   Albassam, M ^c   Kolaja, K L ^c  

^a CELGENE CORPORATION   (United States)

^b MEDIMMUNE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d CorDynamics Inc ^*  (United States)

^e GENENTECH INC   (United States)

Author keywords

Drug induced arrhythmia; Kv11.1; Safety pharmacology; Torsades de pointe

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV11.1; RO 5657; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; BLOOD PRESSURE; CARDIOTOXICITY; CONSCIOUSNESS; CONTROLLED STUDY; DOG; ECG ABNORMALITY; ENZYME INHIBITION; FEMALE; GUINEA PIG; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART RATE; HEART VENTRICLE FIBRILLATION; INCIDENCE; ISOLATED HEART; MACACA FASCICULARIS; MALE; MOLECULAR MECHANICS; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; TELEMETRY; TORSADE DES POINTES;

ANIMALS; BLOOD PRESSURE; DOGS; DRUGS, INVESTIGATIONAL; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GUINEA PIGS; HEART; HEART RATE; HUMANS; MACACA FASCICULARIS; MALE; ORGANIC CHEMICALS; POTASSIUM CHANNEL BLOCKERS; RECEPTORS, CCR5; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TORSADES DE POINTES;

EID: 84859040421     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01756.x     Document Type: Article

References (38)

1. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK (2008). Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 65 (Suppl. 1): 60-67. (Pubitemid 351366540)
2. Ando K, Hombo T, Kanno A, Ikeda H, Imaizumi M, Shimizu N et al. (2005). QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99: 487-500. (Pubitemid 44618149)
3. ANON (2000). Safety pharmacology studies for human pharmaceuticals. ICH S7A CHMP/ICH/439/00, http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002831.pdf.
4. ANON (2005). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. ICH S7B CHMP/ICH/423/02, http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500002841.pdf.
5. Barber CG, Blakemore DC, Chiva JY, Eastwood RL, Middleton DS, Paradowski KA (2009a). 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV: part 2. Bioorg Med Chem Lett 19: 1499-1503.
6. Barber CG, Blakemore DC, Chiva JY, Eastwood RL, Middleton DS, Paradowski KA (2009b). 1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1. Bioorg Med Chem Lett 19: 1075-1079.
7. Cheng HC, Incardona J (2009). Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods 60: 174-184.
8. Cushing DJ, Kowey PR, Cooper WD, Massey BW, Gralinski MR, Lipicky RJ (2009). PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. Eur J Pharmacol 607: 167-172.
9. Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G (2008). Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 65 (Suppl. 1): 68-75. (Pubitemid 351366541)
10. De Clerck F, Van de Water A, D'Aubioul J, Lu HR, van Rossem K, Hermans A et al. (2002). In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundam Clin Pharmacol 16: 125-140. (Pubitemid 34587797)
11. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M et al. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732. (Pubitemid 41552605)
12. Fabritz L, Kirchhof P (2010). Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 106: 263-268.
13. Farkas AS, Nattel S (2010). Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs 70: 573-603.
14. Gintant GA, Su Z, Martin RL, Cox BF (2006). Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 34: 81-90. (Pubitemid 43323264)
15. Giorgi MA, Bolanos R, Gonzalez CD, Di Girolamo G (2010). QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf 5: 54-57.
16. Guerard NC, Traebert M, Suter W, Dumotier BM (2008). Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J Pharmacol Toxicol Methods 58: 32-40.
17. Guo L, Dong Z, Guthrie H (2009). Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J Pharmacol Toxicol Methods 60: 130-151.
18. Guo L, Abrams R, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ et al. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell derived cardiomyocytes. Toxicol Sci 257: 74-83.
19. Gwathmey JK, Tsaioun K, Hajjar RJ (2009). Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin Drug Metab Toxicol 5: 647-660.
20. Hamlin RL (2006). A search to predict potential for drug-induced cardiovascular toxicity. Toxicol Pathol 34: 75-80.
21. Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2008). In vitro models of proarrhythmia. Br J Pharmacol 154: 1516-1522.
22. Ly JQ, Shyy G, Misner DL (2007). Assessing hERG channel inhibition using PatchXpress. Clin Lab Med 27: 201-208. (Pubitemid 46528622)
23. Mansfield R, Able S, Griffin P, Irvine B, James I, Macartney M et al. (2009). CCR5 pharmacology methodologies and associated applications. Methods Enzymol 460: 17-55.
24. Michael G, Dempster J, Kane KA, Coker SJ (2007). Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation. Br J Pharmacol 152: 1215-1227. (Pubitemid 350242442)
25. Nolte S, Doring HJ, Frey A (1987). Mechanically induced ventricular extrasystoles in the isolated perfused guinea-pig heart. A model to study cardiac arrhythmia and to differentiate antiarrhythmic drugs. Arzneimittelforschung 37: 1025-1029. (Pubitemid 17124156)
26. Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159: 12-21.
27. Price DA, Armour D, de Groot M, Leishman D, Napier C, Perros M et al. (2006). Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 16: 4633-4637. (Pubitemid 44094062)
28. Price DA, Armour D, de Groot M, Leishman D, Napier C, Perros M et al. (2008). Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV. Curr Top Med Chem 8: 1140-1151.
29. Pugsley MK, Curtis MJ (2006). Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document. J Pharmacol Toxicol Methods 54: 94-98. (Pubitemid 44293426)
30. Roden DM (2008). Cellular basis of drug-induced torsades de pointes. Br J Pharmacol 154: 1502-1507.
31. Rotstein DM, Gabriel SD, Makra F, Filonova L, Gleason S, Brotherton-Pleiss C et al. (2009). Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett 19: 5401-5406.
32. Sala M, Coppa F, Cappucciati C, Brambilla P, d'Allio G, Caverzasi E et al. (2006). Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs 7: 256-263.
33. Shantsila E, Watson T, Lip GY (2007). Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 9 (Suppl. 4): iv37-iv44.
34. Stummann TC, Beilmann M, Duker G, Dumotier B, Fredriksson JM, Jones RL (2009). Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity. Cardiovasc Toxicol 9: 107-125.
35. Sugiyama A (2008). Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br J Pharmacol 154: 1528-1537.
36. Valentin JP (2010). Reducing QT liability and proarrhythmic risk in drug discovery and development. Br J Pharmacol 159: 5-11.
37. Wallis RM (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 159: 115-121.
38. Yang H, Rotstein DM (2010). Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006-2008. Expert Opin Ther Pat 20: 325-354.